Event Group

Event Group

Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.

Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.

Event Group path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Group

Event Group


Ignite Creation Date: 2025-12-24 @ 7:44 PM
Ignite Modification Date: 2025-12-25 @ 5:22 PM
NCT ID: NCT03461003
Group ID: EG000
Title: NICHE Method
Description: In the NICHE method, antihypertensive therapy will be chosen using an n-of-1 trial to identify the preferred therapy. Preferred therapy is defined a priori as that which produces the greatest reduction in ambulatory BP without intolerable side effects. Tested drugs will include amlodipine or losartan, lisinopril, and hydrochlorothiazide. NICHE method: Based on underlying comorbidities at enrollment, patients will be assigned to either an unrestricted protocol (amlodipine versus lisinopril) or a restricted protocol (losartan versus lisinopril). Two drugs are tested in randomized order. Failure to achieve BP control at maximum doses of the first two drugs will result in augmentation with a diuretic (hydrochlorothiazide). BP control is assessed with 24 hour ambulatory monitoring at the end of each 2 week treatment period. Side effect tolerability is assessed with a questionnaire. Amlodipine: Calcium-channel blocker; antihypertensive Lisinopril: Angiotensin-converting-enzyme (ACE) inhibitor; antihypertensive Hydrochlorothiazide: Thiazide diuretic; antihypertensive Losartan: Angiotensin II receptor blocker (ARB); antihypertensive
Deaths Number Affected: 0
Deaths Number At Risk: None
Serious Number Affected: 0
Serious Number At Risk: 23
Other Number Affected: 0
Other Number At Risk: 23
Study: NCT03461003
Results Section: NCT03461003
Adverse Events Module: NCT03461003